Representatives from the FDA, medical societies, registries and industry met April 22 in Silver Spring, Md., to discuss creation of an international registry for transcatheter aortic valve replacement (TAVR). The collaboration is the first step in an effort to develop a consortium of cardiovascular registries for broad-based analysis and surveillance of medical devices and clinical outcomes.